The Medicines and Healthcare products Regulatory Agency (MHRA), the UK’s regulator for the safety of medical devices, has issued a recall notice for the IV antibiotic Rifadin 600mg, which is manufactured by Aventis Pharma Limited (trading as Sanofi).
Rifadin is an antibiotic used to treat several types of bacterial infection including tuberculosis, leprosy and Legionnaire’s disease. It can be prescribed orally or administered by infusion.
An investigation into “out of trend” results of Rifadin administered by infusion has indicated that batch A5545 was contaminated during manufacture. Sanofi and the MHRA have issued a recall notice for that batch of medication and asked pharmacists, hospitals and relevant clinics to quarantine any remaining stock and to stop using it immediately.
Arran Macleod, a solicitor in the product liability team at Penningtons Manches, said: “It is not clear what “out of trend” results instigated the investigation into the efficacy of this batch of Rifadin. It may be that it has not proved as effective as it should or that it is producing unexpected side effects or complications. Anyone with concerns should contact their GP or treating doctor for advice. As a product liability team, we will be monitoring the situation and are able to advise anyone who feels that they have been adversely affected.”